{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"25","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"The duration of response, defined only among the responders, is measured from start of achieving Partial Response (PR) \\[first observation of PR before confirmation\\] to the time of disease progression, with deaths owing to causes other than progression not counted as events, but censored (Durie et al., 2006). Duration of response will be estimated and plotted with the Kaplan-Meier method. The median will be calculated with 95% confidence intervals.","dispersionType":"Full Range","groups":[{"description":"Lenalidomide Induction (with Low Dose Dexamethasone) Therapy Followed by Low Dose Melphalan, Prednisone, Lenalidomide and Bortezomib Sequential Maintenance Therapy\n\nLenalidomide Induction: Induction: Lenalidomide 25 mg daily on Days 1-21 followed by 7 day rest and Dexamethasone 40 mg by mouth (po) daily on Days 1, 8, 15 and 22 every 28 days for 4 cycles.\n\nSequential Maintenance Therapy: Subjects who achieve \\>partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved \\> stable disease (SD) from maintenance (per discussion with physician):\n\n* 325 mg aspirin for deep vein thrombosis (DVT) prophylaxis\n* Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle\n* Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7\n* Prednisone 60 mg /m2 po daily on","id":"OG000","title":"High-risk Multiple Myeloma"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"6 years","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}